BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/11/2014 8:40:00 PM | Browse: 1299 | Download: 1544
 |
Received |
|
2013-07-19 11:52 |
 |
Peer-Review Started |
|
2013-07-19 23:04 |
 |
First Decision by Editorial Office Director |
|
|
 |
Return for Revision |
|
2013-09-03 21:32 |
 |
Revised |
|
|
 |
Publication Fee Transferred |
|
|
 |
Second Decision by Editor |
|
2013-10-21 17:35 |
 |
Second Decision by Editor-in-Chief |
|
|
 |
Final Decision by Editorial Office Director |
|
2013-10-22 07:41 |
 |
Articles in Press |
|
|
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
2013-11-28 12:10 |
 |
Publish the Manuscript Online |
|
2013-12-18 10:39 |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
Ophthalmologic complications of antiviral therapy in hepatitis C treatment
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Roderick O'Day, Mark C Gillies and Golo Ahlenstiel |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Health and Medical Research Council Project Grant |
APP1006759 |
| Robert W. Storr Bequest to the Sydney Medical Foundation of the University of Sydney |
to Ahlenstiel G |
|
| Corresponding Author |
Dr. Golo Ahlenstiel, Department of Gastroenterology and Hepatology, Westmead Hospital, Hawkesbury Road, Westmead, NSW 2145, Australia. golo.ahlenstiel@sydney.edu.au |
| Key Words |
Interferon; Hepatitis C; Ocular complications; Retinopathy |
| Core Tip |
Interferon-associated retinopathy is usually a benign, transient phenomenon with no lasting impact on visual function. It occurs in approximately 30% of patients receiving antiviral therapy for chronic hepatitis C infection. The main risk factors for its development appear to be hypertension and diabetes. Unless a clear benefit to patients can be shown, a screening program for the development of interferon-associated retinopathy is not justified. No conclusive evidence exists for a causal link between it and the atypical adverse events of antiviral therapy, which tend to cause irreversible vision loss.
|
| Publish Date |
2013-12-18 10:39 |
| Citation |
O’Day R, Gillies MC, Ahlenstiel G. Ophthalmologic complications of antiviral therapy in hepatitis C treatment. World J Gastroenterol 2013; 19(45): 8227-8237
|
| URL |
http://www.wjgnet.com/1007-9327/full/v19/i45/8227.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v19.i45.8227 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.